Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).

In a dose-escalating study of the hypoxia-activating agent tirapazamine in combination with transarterial embolization, patients with intermediate-stage HCC were assigned to 1 of 5 cohorts according to dose.

Results showed that the combination was well tolerated. Additionally, there were no dose-limiting toxicities or serious adverse events reported.

The combination is moving toward a phase II study where it will be compared with chemoembolization, says Abi-Jaoudeh.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Abi-Jaoudeh on Combination of Tirapazamine and Transarterial Embolization in HCC